Tarsus Pharmaceuticals Inc. Common Stock (TARS)
Stock · NASDAQ · Health Care
$71.76as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$60.75
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospit…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 370
- Website
- www.tarsusrx.com/
Fundamentals
- 1-day range
- $70.73$71.84
- Market cap
- $2.64B
- P/E (trailing)
- —
- P/E (forward)
- 30.75
- EPS (trailing)
- $-1.08
- Dividend yield
- —
- Beta
- 0.46
- Avg. volume
- 946.3K
52-week range
$48.2$85.25
Next earnings: November 4, 2026 · EPS estimate $-1.53confirmed
How Tarsus Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 23, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Buy 93%
Hold 7%
Sell 0%
1-year price forecast
High
$104
+44.9%
Median
$99
+38.0%
Low
$84
+17.1%
Tarsus Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TARSTarsus Pharmaceuticals Inc. Common Stock$71.84▼ 0.12%Market cap $2.64BP/E —$48.2$85.25
- BEAMBeam Therapeutics Inc. Common Stock$29.31▼ 3.84%Market cap $2.67BP/E —$16.02$38.26
- KODKodiak Sciences Inc Common Stock$37.77▼ 3.45%Market cap $2.49BP/E —$8.29$47.84
- COAGHemab Therapeutics Holdings Inc. Common Stock$44.77▼ 9.55%Market cap $2.10BP/E —$23$55.42
- MESOMesoblast Limited American Depositary Shares$17.42▼ 4.18%Market cap $1.87BP/E —$1.88$3.31
- RXRXRecursion Pharmaceuticals Inc. Class A Common Stock$3.33▼ 3.20%Market cap $1.69BP/E —$2.77$7.18
- RLAYRelay Therapeutics Inc. Common Stock$18.78▼ 3.30%Market cap $3.60BP/E —$3.5$21.27
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals Inc. Common Stock | $2.64B | — | $71.84 | ▼ 0.12% | $48.2$85.25 |
| BEAM Beam Therapeutics Inc. Common Stock | $2.67B | — | $29.31 | ▼ 3.84% | $16.02$38.26 |
| KOD Kodiak Sciences Inc Common Stock | $2.49B | — | $37.77 | ▼ 3.45% | $8.29$47.84 |
| COAG Hemab Therapeutics Holdings Inc. Common Stock | $2.10B | — | $44.77 | ▼ 9.55% | $23$55.42 |
| MESO Mesoblast Limited American Depositary Shares | $1.87B | — | $17.42 | ▼ 4.18% | $1.88$3.31 |
| RXRX Recursion Pharmaceuticals Inc. Class A Common Stock | $1.69B | — | $3.33 | ▼ 3.20% | $2.77$7.18 |
| RLAY Relay Therapeutics Inc. Common Stock | $3.60B | — | $18.78 | ▼ 3.30% | $3.5$21.27 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100Benzinga · 8/12/2026
- Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M EstimateBenzinga · 8/6/2026
- Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call TranscriptSeekingAlpha · 8/6/2026
- Tarsus Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha · 8/6/2026
- Tarsus Pharmaceuticals To Acquire Alkeus Pharmaceuticals, A Closely Held Biotech Firm Developing Gildeuretinol, An Investigational Once-Daily Oral Therapy For Stargardt Disease; Terms Not DisclosedBenzinga · 8/6/2026
- Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98Benzinga · 7/31/2026
Insider Activity
Insider Actions →Acquired
47.0K
Disposed
40.3K
- Bobak R. Azamian · June 17, 2026 · Sale5.4K @ $61.81
- Bobak R. Azamian · June 17, 2026 · Sale4.6K @ $61.24
- Jeffrey S. Farrow · June 16, 2026 · Sale14.4K @ $60.95
- Jeffrey S. Farrow · June 15, 2026 · Option Exercise27.9K
- William J. Link, PhD · June 15, 2026 · Sale1.9K @ $62.94
- William J. Link, PhD · June 15, 2026 · Sale10.6K @ $61.97
- Katherine Goodrich · June 12, 2026 · Option Exercise3.0K
- Andrew D. Goldberg · June 12, 2026 · Option Exercise3.0K
- Scott W. Morrison · June 12, 2026 · Option Exercise3.0K
- Bhaskar Chaudhuri · June 12, 2026 · Option Exercise3.0K
- William J. Link, PhD · June 12, 2026 · Option Exercise3.0K
- Wendy L. Yarno · June 12, 2026 · Option Exercise3.0K
- David E. I. Pyott · April 24, 2026 · Option Exercise1.4K
- Seshadri Neervannan · March 20, 2026 · Sale3.0K @ $66.75
- Elizabeth Yeu Lin · March 19, 2026 · Sale390 @ $67
Institutional Ownership
March 31, 2026
- Total shares held
- 44.90M
- Total value held
- $3.06B
- Institutional holders
- 246
Top holders this quarter
- Unknown3.60M
- Unknown3.55M
- Unknown3.35M
- Unknown2.56M
- Unknown2.24M
- Unknown1.94M
- Unknown1.76M
- Unknown1.71M
- Unknown1.28M
- Unknown1.19M
See the full, filterable feed with live charts on the MarketWall dashboard.